93 related articles for article (PubMed ID: 23941577)
1. Adjuvant aromatase inhibitor options in overweight and obese postmenopausal women with breast cancer.
Chlebowski RT
Breast J; 2013; 19(5):552-4. PubMed ID: 23941577
[No Abstract] [Full Text] [Related]
2. Obesity and endocrine therapy: host factors and breast cancer outcome.
Goodwin PJ
Breast; 2013 Aug; 22 Suppl 2():S44-7. PubMed ID: 24074791
[TBL] [Abstract][Full Text] [Related]
3. Resolution of endometrial hyperplasia with adjuvant anastrozole treatment in postmenopausal breast cancer: a case report.
Stilwill SE; Cooper BC
J Reprod Med; 2007 Oct; 52(10):979-80. PubMed ID: 17977182
[TBL] [Abstract][Full Text] [Related]
4. Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors.
Lønning PE; Haynes BP; Dowsett M
Eur J Cancer; 2014 Apr; 50(6):1055-64. PubMed ID: 24507547
[TBL] [Abstract][Full Text] [Related]
5. Aromatase inhibitor anastrozole for treating endometrial hyperplasia in obese postmenopausal women.
Agorastos T; Vaitsi V; Pantazis K; Efstathiadis E; Vavilis D; Bontis JN
Eur J Obstet Gynecol Reprod Biol; 2005 Feb; 118(2):239-40. PubMed ID: 15653211
[TBL] [Abstract][Full Text] [Related]
6. Aromatase inhibitors in the treatment of early and advanced breast cancer.
Joensuu H; Ejlertsen B; Lønning PE; Rutqvist LE
Acta Oncol; 2005; 44(1):23-31. PubMed ID: 15848903
[TBL] [Abstract][Full Text] [Related]
7. Obesity and nonadherence correlate with elevated serum estradiol levels in postmenopausal women receiving adjuvant aromatase inhibitor therapy.
Decker DA; Reynolds RB; Molthrop DC; Griffith E; Encarnacion T; Lee E; Zhu X
Breast J; 2014; 20(5):553-4. PubMed ID: 25088121
[No Abstract] [Full Text] [Related]
8. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
[TBL] [Abstract][Full Text] [Related]
9. Retrospective analysis of concurrent vs. sequential administration of radiotherapy and hormone therapy using aromatase inhibitor for hormone receptor-positive postmenopausal breast cancer.
Ishitobi M; Komoike Y; Motomura K; Koyama H; Nishiyama K; Inaji H
Anticancer Res; 2009 Nov; 29(11):4791-4. PubMed ID: 20032437
[TBL] [Abstract][Full Text] [Related]
10. NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancer.
Mamounas EP; Lembersky B; Jeong JH; Cronin W; Harkins B; Geyer C; Wickerham DL; Paik S; Costantino J; Wolmark N
Clin Breast Cancer; 2006 Dec; 7(5):416-21. PubMed ID: 17239269
[No Abstract] [Full Text] [Related]
11. Letrozole.
Dellapasqua S; Colleoni M
Expert Opin Drug Metab Toxicol; 2010 Feb; 6(2):251-9. PubMed ID: 20095792
[TBL] [Abstract][Full Text] [Related]
12. A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients' persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer.
Yu KD; Zhou Y; Liu GY; Li B; He PQ; Zhang HW; Lou LH; Wang XJ; Wang S; Tang JH; Liu YH; Wang X; Jiang ZF; Ma LW; Gu L; Cao MZ; Zhang QY; Wang SM; Su FX; Zheng H; Li HY; Tang LL; Sun SR; Liu JP; Shao ZM; Shen ZZ
Breast Cancer Res Treat; 2012 Jul; 134(1):307-13. PubMed ID: 22527106
[TBL] [Abstract][Full Text] [Related]
13. Aromatase inhibitors in obese breast cancer patients are not associated with increased plasma estradiol levels.
Diorio C; Lemieux J; Provencher L; Hogue JC; Vachon E
Breast Cancer Res Treat; 2012 Nov; 136(2):573-9. PubMed ID: 23053662
[TBL] [Abstract][Full Text] [Related]
14. Resumption of menses with initiation of letrozole after five years of amenorrhea on tamoxifen: caution needed when using tamoxifen followed by aromatase inhibitors.
Hargis JB; Nakajima ST
Cancer Invest; 2006 Mar; 24(2):174-7. PubMed ID: 16537187
[TBL] [Abstract][Full Text] [Related]
15. Letrozole as adjuvant endocrine therapy in postmenopausal women with breast cancer.
Koeberle D; Thuerlimann B
Expert Rev Anticancer Ther; 2006 Jan; 6(1):5-10. PubMed ID: 16375638
[TBL] [Abstract][Full Text] [Related]
16. Another pill for breast cancer prevention.
Johns Hopkins Med Lett Health After 50; 2014 Mar; 26(1):8. PubMed ID: 24937851
[No Abstract] [Full Text] [Related]
17. [Aromatase inhibitors: anastrozole versus tamoxifen as first-ine therapy for advanced postmenopausal breast cancer].
Bergmann L
Strahlenther Onkol; 2001 May; 177(5):273-4. PubMed ID: 11398617
[No Abstract] [Full Text] [Related]
18. Should all postmenopausal patients with hormone receptor-positive breast cancer receive initial therapy with aromatase inhibitors?
Aapro M; van de Velde CJ; Markopoulos C; Bartlett JM; Putter H; Coleman RE
Breast; 2013 Aug; 22(4):488-94. PubMed ID: 23454040
[TBL] [Abstract][Full Text] [Related]
19. Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer.
Pfeiler G; Königsberg R; Hadji P; Fitzal F; Maroske M; Dressel-Ban G; Zellinger J; Exner R; Seifert M; Singer C; Gnant M; Dubsky P
Br J Cancer; 2013 Sep; 109(6):1522-7. PubMed ID: 24002592
[TBL] [Abstract][Full Text] [Related]
20. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data.
Buzdar AU; Cuzick J
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1037s-1048s. PubMed ID: 16467122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
